At MORSE Consulting, we’re delighted to share insights from Sherry O’Quinn’s recent participation at the Rare Disease Day 2024 Summit held by the Canadian Organization for Rare Disorders (CORD) in Ottawa. The conference, themed around sustaining the momentum of two decades of impactful work in the rare disease community, was insightful and inspiring.
Sherry had the opportunity to present a snapshot on the timelines to access for drugs for rare diseases (DRDs) in Canada, setting the context to better understand the challenges and to set the stage for participants in the conference to propose meaningful solutions. During her panel, Sherry presented data on the number of positive recommendations released by CADTH and INESSS for DRDs over the last 3-5 years and reported on the level of discordance between recommendations.
She also displayed data that shows significant variability in timelines for negotiations, presenting both areas of progress as well as challenges. Sherry emphasized the feasibility and achievability of key objectives, including the development of a risk mitigation framework, enhanced transparency, improved early multi-stakeholder dialogue, and alignment with ongoing collaborative efforts already underway.
Download our presentation to learn more about “Canadian Pathway to Rare Disease Drug Access”:
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
